Feature

Q&A: Network aims to boost underrepresented populations in cardiac surgery trials

September 19, 2019
The Keck School of Medicine of the University of Southern California received a $4.5 million grant from the NIH and NHLBI to fund efforts in…
In the Journals

Polypill strategy effective in US socioeconomically disadvantaged population

September 18, 2019
Among a U.S. population of socioeconomically disadvantaged adults, a polypill-based strategy was associated with greater reductions in systolic BP…
In the Journals

No patients with prediabetes referred to prevention program

September 18, 2019
None of the more than 1,400 patients with prediabetes were formally referred to the CDC’s National Diabetes Prevention Program, according to…
FDA News

Sirolimus-eluting balloon given breakthrough device designation

September 18, 2019
Orchestra BioMed Inc., in partnership with Terumo Corporation, announced its sirolimus-eluting balloon for the treatment of below-the-knee peripheral…
Meeting News

Early ICD use prolongs survival after coronary stenting

September 18, 2019
PARIS — Early use of an implantable cardioverter defibrillator after primary PCI lengthened survival among high-risk patients with STEMI…
Meeting NewsVideo

VIDEO: Top takeaways from ESC Congress with Deepak L. Bhatt, MD, MPH

September 18, 2019
PARIS — In this video exclusive, Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and…
Meeting News

Supplemental high-flow oxygen not beneficial for suspected ACS

September 18, 2019
PARIS — Among patients with suspected acute coronary syndromes, new data from the NZOTACS trial show no difference in 30-day mortality for…
Meeting News

Q&A: Shaq gets real about HF awareness in black population

September 17, 2019
PHILADELPHIA — Shaquille O’Neal, PhD, FHSFA, retired basketball star and winner of four NBA championships, discussed the recently…
In the Journals

COMPASS: Low-dose rivaroxaban plus aspirin confers reduced embolic stroke risk

September 17, 2019
According to new data from the COMPASS trial, patients with systemic atherosclerosis assigned low-dose rivaroxaban plus aspirin had reduced risk for…
Meeting News

TRI-REPAIR: Valve reconstruction system reduces tricuspid regurgitation at 1 year

September 17, 2019
PHILADELPHIA — The success of a transcatheter tricuspid valve reconstruction system in patients with tricuspid regurgitation was maintained at…
Meeting News

LV end-diastolic pressure significant marker for outcomes after heart catheterization

September 17, 2019
PHILADELPHIA — Following left heart catheterization, offloading measured by left ventricular end-diastolic pressure was a notable marker for…
Meeting News

Virtual visits feasible for patients transitioning to home after HF: ViV-HF

September 16, 2019
PHILADELPHIA — The Virtual Visits and Heart Failure Care Transition, or ViV-HF, trial proved the feasibility of substituting inpatient visits…
In the Journals

Some people without CVD may benefit from aspirin regimen

September 16, 2019
If one CVD event was considered to be equivalent to one major bleed, 2.5% of women and 12.1% of men without CVD were likely to have a 5-year net…
Meeting News

AMBER: Patiromer enables persistent spironolactone treatment in patients with hypertension, CKD

September 16, 2019
PHILADELPHIA — Concomitant use of the potassium binder patiromer enabled more patients with resistant hypertension and advanced chronic kidney…
Meeting NewsPerspective

PARAGON HF Echo: RV enlargement among predictors of events in HFpEF

September 16, 2019
PHILADELPHIA — Right ventricular enlargement, left ventricular hypertrophy and elevated left- and right-sided pressures were among the…
Meeting NewsPerspective

DEFINE-HF: Dapagliflozin improves HF-related health regardless of diabetes status

September 16, 2019
PHILADELPHIA — In patients with HF with reduced ejection fraction with or without diabetes, the SGLT2 inhibitor dapagliflozin was associated…

FDA grants fast track designation to dapagliflozin for worsening heart failure

September 16, 2019
The FDA has granted fast track designation to the SGLT2 inhibitor dapagliflozin for reducing the risk for cardiovascular death or worsening heart…
Meeting News

HF prevalence, disparities continue to widen in black communities

September 14, 2019
PHILADELPHIA — Over time, the disparity gap in HF prevalence among black adults compared with white adults has widened and the odds of HF…
Meeting News

ATTR-ACT: Tafamidis improves quality of life in transthyretin amyloid cardiomyopathy

September 14, 2019
PHILADELPHIA — Tafamidis was associated with improvements in a variety of metrics of quality of life in patients with transthyretin amyloid…
Meeting News

Explanation of HF disparities more complicated than race

September 14, 2019
PHILADELPHIA — While HF is more prevalent in the black population than in the white population, reasons for the disparity are more complicated…